Basically, even if there was a prolonged progression-free survival, OS was not statistically different in the two arms.
BUT a strong survival advantage was seen in patients with liver metastasis!
ESMO 2024: Cabozantinib plus Atezoliz... - Advanced Prostate...
ESMO 2024: Cabozantinib plus Atezolizumab versus 2nd novel hormonal therapy inmetastatic CRPC, overall survival results of CONTACT-02 Study
Written by
Maxone73
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Metformin: Preliminary Results of Trial in Advanced Prostate Cancer (MANSMED)
Not sure if this was posted here yet:
In a mini-oral presentation at this year’s European Society...
Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with mHSPC
“the research suggests a differential impact between androgen receptor antagonists (like...
Tolerability and treatment response to darolutamide in patients with nmCRPC in the phase III ARAMIS trial
Darolutamide was well tolerated by most patients. Effectiveness related to the PSA decline from...
Related Posts
Survival after radiotherapy vs. radical prostatectomy for unfavorable intermediate-risk prostate cancer- Statin use in advanced PCA with ADT or abiraterone/enzalutamide
SRT or ART? I was about to do ART but read these studies just in time (less than 2 weeks before radiation was going to start). - Benefits of intermittent/continuous androgen deprivation in patients with advanced prostate cancer.
Apalutamide for Metastatic Castration-Sensitive Prostate Cancer
